Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Oct 15 - Oct 20
About Epithalon Research Epithalon is a synthetic tetrapeptide investigated in published scientific literature involving peptide biology, telomere biology, cellular aging research models, molecular signaling pathways, gene expression studies, and experimental peptide pharmacology
Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions
No complicated steps, no guesswork
Check your genes, read the new studies on interventions, and understand the mechanisms
A 50mg vial with 5mL yields 10mg/mL a 5mg dose requires 0.5mL (50 units), easier to measure accurately than 0.2mL at 25mg/mL concentration
US$ 21.48
US$ 28.72
US$ 23.78
US$ 20.90
US$ 23.05
US$ 24.12
